Aligos Therapeutics (ALGS) Accumulated Expenses (2019 - 2026)

Aligos Therapeutics has reported Accumulated Expenses for 8 years, with the latest figure at $12.0 million in Q1 2026.

• For the quarter ending Q1 2026, Accumulated Expenses rose 247.61% year-over-year to $12.0 million; the trailing twelve-month figure through Mar 2026 stood at $12.0 million (up 247.61% YoY), and the FY2025 full-year result was $13.5 million, down 13.06% from the prior year.
• Accumulated Expenses for Q1 2026 stood at $12.0 million, down from $13.5 million in the prior quarter.
• The five-year high for Accumulated Expenses was $19.2 million in Q1 2022, with the low at $3.1 million in Q1 2023.
• Historically, Accumulated Expenses has averaged $10.1 million across 5 years, with a median of $12.0 million in 2024.
• Annual changes were most pronounced in 2022 — Accumulated Expenses soared 388.18% — and 2023, when it plunged 83.96%.
• Aligos Therapeutics' Accumulated Expenses stood at $16.0 million in 2022, then rose by 5.01% to $16.8 million in 2023, then slipped by 7.63% to $15.6 million in 2024, then dropped by 13.06% to $13.5 million in 2025, then slipped by 11.36% to $12.0 million in 2026.
• The last three Accumulated Expenses figures came in at $12.0 million (Q1 2026), $13.5 million (Q4 2025), and $13.6 million (Q3 2025), per Business Quant data.